Nov. 14 at 2:24 PM
$MDAI Part III:
Analyst Price Targets: Current Wall Street analysts covering Spectral AI have an average 12-month price target ranging from approximately
$3.25 to
$4.83, with some high forecasts up to
$6.00. These targets suggest a potential increase from the current price (which has recently traded in the
$1.60 -
$2.30 range), not a guaranteed return to the mid-
$2 range after a brief pop. Analysts currently have a "Strong Buy" or "Hold" consensus rating for the stock, indicating a belief in long-term potential.
Revenue Generation: While FDA approval is a major milestone, significant revenue generation for new medical devices often takes time to ramp up due to the sales cycle, hospital adoption, and insurance reimbursement processes. The company has a contract with BARDA (Biomedical Advanced Research and Development Authority) that ensures the purchase of at least 200 DeepView units, which will provide a solid initial revenue stream post-approval.
